[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-462023-105":59,"doc-detail-462023-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","potential-biomarker-and-therapeutic-tools-for-pathological-cardiac-hypertrophy-and-heart-failure-extracellular-vesicles","Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure - Extracellular Vesicles","","Cardiovascular disease remains the leading global cause of death, and pathological cardiac hypertrophy is a key precursor to heart failure (HF) marked by high morbidity and mortality. Extracellular vesicles (EVs) function as critical mediators of intercellular communication, transporting bioactive cargo that mirrors cellular state and reshapes recipient behavior. This review analyzes cell-type-specific EV roles from pathological hypertrophy to overt HF, integrating evidence on maladaptive remodeling orchestrated by cardiomyocyte, fibroblast, immune, and adipocyte-derived EVs. It also evaluates EVs as diagnostic biomarkers and engineerable therapeutic vectors, addressing translational hurdles to advance cardiovascular applications.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/potential-biomarker-and-therapeutic-tools-for-pathological-cardiac-hypertrophy-and-heart-failure-extracellular-vesicles/462023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/potential-biomarker-and-therapeutic-tools-for-pathological-cardiac-hypertrophy-and-heart-failure-extracellular-vesicles/462023.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role do extracellular vesicles (EVs) play in the transition from pathological cardiac hypertrophy to heart failure?","Question",{"text":113,"@type":114},"EVs act as essential conduits for cell-to-cell communication by carrying proteins, lipids, and nucleic acids. They modulate recipient cell phenotypes and help orchestrate maladaptive remodeling across the hypertrophy-to-HF continuum.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are EVs considered promising diagnostic biomarkers for heart failure?",{"text":118,"@type":114},"EVs carry bioactive cargoes that reflect the cellular state. The review evaluates how EVs derived from multiple cardiac cell types can provide information linked to HF of varied etiologies.",{"name":120,"@type":111,"acceptedAnswer":121},"How do engineered EVs support therapeutic development, and what challenges remain?",{"text":122,"@type":114},"Engineered EVs are described as engineerable therapeutic vectors enabling targeted delivery. The review discusses recent advances in EV engineering while highlighting persistent translational challenges and future directions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},462023,1791089661,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nPotential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure: Extracellular Vesicles  \nJinpeng Sun 1,2,3,†, Dongli Zhou 1,2,3,† and Min Cheng 1,2,3, *  \nAcademic Editor: Anastasios Lymperopoulos  \nReceived: 18 November 2025  \nRevised: 14 December 2025  \nAccepted: 18 December 2025  \nPublished: 22 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; [sunsunjinjin@163.com](sunsunjinjin@163.com) (J.S.); [zdl1020@hust.edu.cn](zdl1020@hust.edu.cn) (D.Z.)  \n2 Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China  \n3 Hubei Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China  \n* [Correspondence: min_cheng@hust.edu.cn](Correspondence: min_cheng@hust.edu.cn)  \n† These authors contributed equally to this work.  \nAbstract  \nCardiovascular disease remains the leading global cause of death. Pathological cardiac hypertrophy is a key precursor to heart failure (HF), a condition with high morbidity and mortality. Extracellular vesicles (EVs) have emerged as crucial mediators of intercellular communication, carrying bioactive cargoes that reflect cellular state and influence recipient cell function. This review provides a focused and integrative perspective distinct from broader overviews, by dissecting the dynamic, cell-type-specific roles of EVs across the continuum from pathological hypertrophy to overt HF. We critically synthesize evidence on how EVs derived from cardiomyocytes, fibroblasts, immune cells, and adipocytes orchestrate maladaptive remodeling. Furthermore, we evaluate their dual utility as emerging diagnostic biomarkers and as engineerable therapeutic vectors. By highlighting recent advances in EV engineering for targeted delivery and discussing persistent translational challenges, this article offers a unique mechanistic-to-translational viewpoint aimed at advancing the therapeutic application of EVs in cardiovascular medicine.  \nKeywords: extracellular vesicles; exosomes; cardiac hypertrophy; heart failure; microRNA  \n1. Introduction  \nHeart failure (HF) represents the common end-stage of numerous cardiovascular diseases, characterized by a complex pathophysiology involving neurohormonal activation, inflammatory responses, and extensive myocardial remodeling [1] . Cardiac hypertrophy, initially a compensatory response to stress, becomes pathological and a major risk factor for HF when sustained [2] . Understanding the intercellular crosstalk that drives this detrimental transition is paramount. Beyond direct contact and soluble factors, extracellular vesicles (EVs) have been recognized as essential conduits for cell-to-cell communication, shuttling proteins, lipids, and nucleic acids to modulate recipient cell phenotype [3] .  \nWhile the general roles of EVs in cardiovascular health and disease have been reviewed [4,5], there is a need for a focused analysis on their specific functions within the pathological hypertrophy-to-HF axis. This axis involves a coordinated yet dysregulated dialogue among cardiac cell types. Recent reviews have covered EVs in broad  \ncardiovascular contexts [6], specific microRNA (miRNA) families [7], or general therapeutic potential [8] . This manuscript distinguishes itself by providing an integrated, cellcentric, and dynamic analysis of how EVs from defined cellular sources (cardiomyocytes, fibroblasts, macrophages, adipocytes) contribute to specific stages of disease progression. The study aims to (1) de","cbCaig8PpInrFV0F","https://ap.wps.com/l/cbCaig8PpInrFV0F","pdf",1247098,28,"English","# Abstract\n# Introduction\n# Biogenesis and Function of EVs and Exosomes","[{\"question\":\"What role do extracellular vesicles (EVs) play in the transition from pathological cardiac hypertrophy to heart failure?\",\"answer\":\"EVs act as essential conduits for cell-to-cell communication by carrying proteins, lipids, and nucleic acids. They modulate recipient cell phenotypes and help orchestrate maladaptive remodeling across the hypertrophy-to-HF continuum.\"},{\"question\":\"Why are EVs considered promising diagnostic biomarkers for heart failure?\",\"answer\":\"EVs carry bioactive cargoes that reflect the cellular state. The review evaluates how EVs derived from multiple cardiac cell types can provide information linked to HF of varied etiologies.\"},{\"question\":\"How do engineered EVs support therapeutic development, and what challenges remain?\",\"answer\":\"Engineered EVs are described as engineerable therapeutic vectors enabling targeted delivery. The review discusses recent advances in EV engineering while highlighting persistent translational challenges and future directions.\"}]","Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure - Extracellular Vesicles | PDF",1790763064,71,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/5cdd13e2f68e32add1988571f93fb93a.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/f0ba337d235342be521af19154d45eac.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ba496aa9c5540d7d8503e32f7fbf3387.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/25043be5a8aa1827d4d4faaa0a41fd0c.webp",980,1385]